Literature DB >> 6476952

Effects of preoperative duration of symptoms on patients with myasthenia gravis.

Y Monden, K Nakahara, K Kagotani, Y Fujii, S Nanjo, A Masaoka, Y Kawashima.   

Abstract

In 80 patients with type II nonthymomatous myasthenia gravis who underwent extended thymectomy, we investigated preoperative duration of symptoms, prognosis after thymectomy, immunological findings, and germinal center formation in the thymus. Our findings included the following. First, the palliation rate after thymectomy ranged from 73 to 100% and was independent of the preoperative duration of symptoms. The remission rate was high in patients with a short preoperative duration. Second, the lymphocyte count of peripheral blood decreased as preoperative duration increased. Third, the percentage of positive reactions to purified protein derivative of tuberculin decreased as preoperative duration increased: 100% in the one-year group, 78% in the two-year group, 75% in the three-year group, and 56% in the four-year group. Fourth, the degree of germinal center formation in the thymus was higher in patients with a longer preoperative duration. The correlation between germinal center formation and preoperative duration was significant. Finally, the T-cell population in peripheral blood and immunoglobulin, and antibody to acetylcholine receptor in serum, had no significant relationship with the preoperative duration of myasthenia gravis.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6476952     DOI: 10.1016/s0003-4975(10)62253-9

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  8 in total

Review 1.  Perioperative management in myasthenia gravis: republication of a systematic review and a proposal by the guideline committee of the Japanese Association for Chest Surgery 2014.

Authors:  Yoshihisa Kadota; Hirotoshi Horio; Takeshi Mori; Noriyoshi Sawabata; Taichiro Goto; Shin-ichi Yamashita; Takeshi Nagayasu; Akinori Iwasaki
Journal:  Gen Thorac Cardiovasc Surg       Date:  2015-01-22

2.  Thymus in myasthenia gravis. Isolation of T-lymphocyte lines specific for the nicotinic acetylcholine receptor from thymuses of myasthenic patients.

Authors:  A Melms; B C Schalke; T Kirchner; H K Müller-Hermelink; E Albert; H Wekerle
Journal:  J Clin Invest       Date:  1988-03       Impact factor: 14.808

3.  Thymectomy for Myasthenia Gravis.

Authors:  Gary S. Gronseth; Richard J. Barohn
Journal:  Curr Treat Options Neurol       Date:  2002-05       Impact factor: 3.598

Review 4.  Ocular myasthenia gravis. A critical review of clinical and pathophysiological aspects.

Authors:  N Sommer; A Melms; M Weller; J Dichgans
Journal:  Doc Ophthalmol       Date:  1993       Impact factor: 2.379

5.  Actuarial analysis of the occurrence of remissions following thymectomy for myasthenia gravis in 400 patients.

Authors:  L Durelli; G Maggi; C Casadio; R Ferri; S Rendine; L Bergamini
Journal:  J Neurol Neurosurg Psychiatry       Date:  1991-05       Impact factor: 10.154

6.  Thymectomy for myasthenia gravis: 14-year experience.

Authors:  J R Hankins; R F Mayer; J R Satterfield; S Z Turney; S Attar; A J Sequeira; B W Thompson; J S McLaughlin
Journal:  Ann Surg       Date:  1985-05       Impact factor: 12.969

7.  Autoimmune Myasthenia Gravis: Recommendations for Treatment and Immunologic Modulation.

Authors:  Vern C Juel; Janice M Massey
Journal:  Curr Treat Options Neurol       Date:  2005-01       Impact factor: 3.972

Review 8.  Myasthenia gravis.

Authors:  Vern C Juel; Janice M Massey
Journal:  Orphanet J Rare Dis       Date:  2007-11-06       Impact factor: 4.123

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.